Xiong-Jian Xiao

Xiong-Jian Xiao

Auto-generated profile, based on publicly available information

Xiong-Jian Xiao

Department of Critical Care Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HLHai-Rong Lin
Hai-Rong Lin
QLQiu-Xia Liao
Qiu-Xia Liao
XLXin-Xin Lin
Xin-Xin Lin
YZYe Zhou
Ye Zhou
JLJian-Dong Lin
Jian-Dong Lin
XXXiong-Jian Xiao
Xiong-Jian Xiao
In this study, we aimed to investigate the risk factors associated with in-hospital mortality in patients with cirrhosis and sepsis, establish and validate the nomogram. This retrospective study included patients diagnosed with liver cirrhosis and sepsis in the Medical Information Mart for Intensive Care IV (MIMIC-IV). Models were compared by the area under the curve (AUC), integrated discriminant improvement (IDI), net reclassification index (NRI) and decision curve analysis (DCA). A total of 1,696 patients with cirrhosis and sepsis were included in the final cohort. Our final model included the following 9 variables: age, heartrate, total bilirubin (TBIL), glucose, sodium, anion gap (AG), fungal infections, mechanical ventilation, and vasopressin. The nomogram were constructed based on these variables. The AUC values of the nomograms were 0.805 (95% CI 0.776–0.833), which provided significantly higher discrimination compared to that of SOFA score [0.684 (95% CI 0.647–0.720)], MELD-Na [0.672 (95% CI 0.636–0.709)] and ABIC [0.674(95% CI 0.638–0.710)]. We established the first nomogram for predicting in-hospital mortality in patients with liver cirrhosis and sepsis based on these factors. This nomogram can performs well and facilitates clinicians to identify people at high risk of in-hospital mortality.

14 February 2020 in Chinese Medical Journal
Verified
Journal Article
Open access
JSJun-Feng Su
Jun-Feng Su
DLDao-Ping Le
Dao-Ping Le
CLChun-He Liu
Chun-He Liu
JLJian-Dong Lin
Jian-Dong Lin
XXXiong-Jian Xiao
Xiong-Jian Xiao
An abstract is unavailable. This article is available as a PDF only.

6 August 2024 in Renal Failure
Verified
Journal Article
Open access
BLBingwen Lin
Bingwen Lin
WXWenbiao Xiao
Wenbiao Xiao
PHPeng Huang
Peng Huang
XLXinxin Lin
Xinxin Lin
YLYuanxi Lin
Yuanxi Lin
XXXiongjian Xiao
Xiongjian Xiao
In various disease contexts, magnesium abnormalities are associated with acute kidney injury (AKI) incidence. However, this association remains unclear and has not been systematically investigated in patients with cirrhosis. Hence, we aimed to elucidate the association between admission serum magnesium levels and AKI incidence in intensive care unit (ICU)-admitted cirrhotic patients. A retrospective cohort study was conducted using MIMIC-IV2.2 data, focusing on critically ill patients with cirrhosis. We employed univariable and multivariable logistic regression and restricted cubic spline analyses to robustly address our research objectives. To further substantiate the findings, subgroup and sensitivity analyses were also conducted. Among the 3,228 enrolled ICU-admitted cirrhotic patients, 34.4% were female, and the overall AKI incidence was 68.6% (2,213/3,228). Multivariable logistic regression analysis revealed an independent relationship between elevated serum magnesium levels and increased AKI risk (OR = 1.55 [95% CI = 1.15-2.09], p = 0.004). Compared with individuals with serum magnesium levels < 1.6 mg/dL, individuals with serum magnesium levels in Q2 (1.6-2.6 mg/dL) and Q3 (≥2.6 mg/dL) had adjusted ORs for AKI of 1.89 (95% CI = 1.34-2.65, p < 0.001) and 2.19 (95% CI = 1.27-3.75, p = 0.005), respectively. The restricted cubic spline analysis revealed that AKI risk increased linearly with increasing serum magnesium levels. Subgroup analysis revealed that the association between serum magnesium levels and AKI incidence was remarkably stable in subgroup analysis (all Pinteraction >0.05). High serum magnesium concentrations were significantly associated with an increased AKI risk in ICU-admitted patients with cirrhosis. Further randomized trials are needed to confirm this association.

11 October 2023 in Journal of Intensive Medicine
Verified
Journal Article
Open access
JSJunfeng Su
Junfeng Su
YWYing Wang
Ying Wang
JXJing Xie
Jing Xie
LCLong Chen
Long Chen
XLXinxin Lin
Xinxin Lin
XXXiongjian Xiao
Xiongjian Xiao
Background: Acute kidney injury (AKI) is a primary feature of renal complications in patients with sepsis. MicroRNA (miRNA/miR)-30a is an essential regulator of cardiovascular diseases, tumors, phagocytosis, and other physical processes, but whether it participates in sepsis-induced AKI (sepsis-AKI) is unknown. We aimed to elucidate the functions and molecular mechanism underlying miR-30a activity in sepsis-AKI. Methods: The classical cecal ligation and puncture (CLP) method and lipopolysaccharide (LPS)-induced Human Kidney 2 (HK-2) cells were used to establish in vivo and in vitro sepsis-AKI models. Specific pathogen-free and mature male Sprague-Dawley (SD) rats, aged 6–8 weeks (weight 200–250 g), were randomly divided into five-time phase subgroups. Fluid resuscitation with 30 mL/kg 37 °C saline was administered after the operation, without antibiotics. Formalin-fixed, paraffin-embedded kidney sections were stained with hematoxylin and eosin. SD rat kidney tissue samples were collected for analysis by real-time quantitative polymerase chain reaction and enzyme-linked immunosorbent assay. HK-2 cells were transfected with hsa-miR-30a-3p mimics or inhibitors, and compared with untreated normal controls. RNA, protein, and cell viability were evaluated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR), western blot, and cell counting kit-8 methods. A Dual-Luciferase Assay Kit (Promega) was used to measure luciferase activity 48 h after transfection with miR-30a-3p mimics. Results: Expression levels of miR-30a-3p and miR-30a-5p in renal tissues of the sepsis group were significantly reduced at 12 h and 24 h (P <0.05). Tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were significantly increased in renal tissue 3 h after the operation in rats (P <0.05), and gradually decreased 6 h, 12 h, and 24 h after CLP. Levels of miR-30a-5p and miR-30a-3p were significantly down-regulated at 3 h after LPS treatment (P <0.05), and gradually decreased in HK-2 cells. One hour after LPS (10 µg/mL) treatment, TNF-α and IL-1β levels in HK-2 cells were significantly up-regulated (P < 0.05), and they were markedly down-regulated after 3 h (P <0.05). IL-6 expression levels began to rise after LPS treatment of cells, peaked at 6 h (P <0.05), and then decreased to the initial level within a few hours. Stimulation with 10 µg/mL LPS promoted HK-2 cells proliferation, which was inhibited after miR-30a-3p-mimic transfection. Bioinformatics prediction identified 37 potential miR-30a-3p target genes, including transcriptional enhanced associate domain 1 (TEAD1). After transfection of HK-2 cells with miR-30a-3p mimics and miR-30a-3p inhibitor, TEAD1 transcript was significantly up- and down-regulated, respectively (both P <0.05). After LPS treatment (24 h), expression of TEAD1 in the inhibitors group was significantly increased (P <0.01), while that in the mimics group was significantly suppressed (P <0.01). In the dual luciferase reporter experiment, miR-30a-3p overexpression decreased fluorescence intensity (P <0.01) from TEAD1-wt-containing plasmids, but did not influence fluorescence intensity from TEAD1-muta-containing plasmids. LPS may promote HK-2 cells proliferation through the miR-30a-3p/TEAD1 pathway. Conclusion: In a background of expression of inflammatory factors, including TNF-α, IL-1β, and IL-6, which were transiently increased in the sepsis-AKI model, miR-30a was down-regulated. Down-regulated miR-30a-3p may promote cell proliferation by targeting TEAD1 in LPS-induced HK-2 cells, demonstrating its potential as a biomarker for early sepsis-AKI diagnosis.

17 March 2025 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
YWYing Wang
Ying Wang
GDGao-Fan Dai
Gao-Fan Dai
WXWen-Biao Xiao
Wen-Biao Xiao
JSJing-Shi Shi
Jing-Shi Shi
BLBing-Wen Lin
Bing-Wen Lin
XXXiong-Jian Xiao
Xiong-Jian Xiao

26 January 2023 in Research Square
Verified
Preprint
Open access
PDF file
YWYing Wang
Ying Wang
JLJian-Dong Lin
Jian-Dong Lin
WXWen-Biao Xiao
Wen-Biao Xiao
XXXiong-Jian Xiao
Xiong-Jian Xiao
Background: There is a debt whether prophylactic antibiotic use may further hamper prognosis of patients with OHCA. In this study, we have performed a meta-analysis to assessed the effect of prophylactic antibiotic administration. Methods: Electronic databases were searched for trials in which prophylactic antibiotic had been administered to adults with OHCA. The predefined primary outcome was the incidence of pneumonia. Results: The included 6 trials enrolled a total of 5061 patients. Prophylactic antibiotic administration was not associated with decreased incidence of pneumonia and early-onset pneumonia (OR 0.44; 95%CI (0.19, 1.02); p= 0.056; I2=95.9% vs. OR 0.54; 95%CI (0.22, 1.32); p= 0.175; I2=46.8%). No adverse effect on mortality was found among trials (OR 1.17; 95%CI (0.46, 2.97); p= 0.748; I2=87.8%). Conclusion: Given this conflicting collection of limited quality, no difference in the incidence of pneumonia (including early-onset pneumonia) and mortality was found when receiving prophylactic antibiotic administration in patients suffering out-of-hospital cardiac arrest. Randomized trials are warranted to define the best prophylactic antibiotic protocol. PROSPERO registration number: CRD42022341601. 07 March, 2022 retrospectively registered.